Greenway analysis estimates AI-enabled automation in Nevada alone could create up to $9.0 million in potential annual value, including approximately $8.0 million from increased patient capacity and $1.0 million from revenue-cycle improvements

In addition, Vivos expects to save $1.8 million annually from Greenway’s recovery of an estimated 46,000+ employee hours, while creating capacity for nearly 30,000 additional patient visits

LITTLETON, Colo., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea ("OSA") and other sleep related breathing disorders, today announced an expanded strategic engagement with Greenway Health, a leading healthcare technology company, to deploy Greenway’s new AI-by-design Novare platform across Vivos’ growing clinical operations. Program implementation has already begun at Sleep Centers of Nevada.

Following Greenway’s extensive analysis of operational data from Sleep Centers of Nevada (SCN), Greenway estimates that implementation of their Novare and related workflow automation could potentially generate approximately $9.1 million of annual value creation for Vivos at SCN. On top of that, Vivos estimates potential additional savings of up to $1.8 million annually at SCN from the estimated 46,000+ annual recovered labor hours. Vivos believes the combination of incremental revenue capacity and reduced administrative workload could create meaningful operating leverage as the Company grows.